Xenova Pathfinder Issued

4 November 1996

UK biotechnology firm Xenova has issued its pathfinder prospectus for a listing on the London Stock Exchange (Marketletter September 30). The firm, which has been quoted on the Nasdaq in the USA since 1994, plans to raise around L25 million ($40.3 million).

It is anticipated that the terms of the placing should be announced, and the final listing particulars published, in the second half of November. Xenova will use the proceeds to progress development of its most advanced drug candidates, to establish facilities and research teams at its US subsidiary, MetaXen, and to support its drug discovery and lead optimization programs, it said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight